Phase II study combining gefitinib with etoposide in patients with hormone-refractory metastatic prostate cancer (mHRPC) after docetaxel-based therapy.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. e15071-e15071
Author(s):  
R. J. Hauke ◽  
F. R. Loberiza ◽  
J. E. Elkahwaji ◽  
P. M. Townley ◽  
G. K. Bascom ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Phase Ii ◽  
Metastatic Prostate Cancer ◽  
Phase Ii Study ◽  
Hormone Refractory

Phase II study of paclitaxel and vinorelbine (Pacl-Vin) in hormone-refractory metastatic prostate cancer: double tubulin targeting

2010 ◽  
Vol 40 (3) ◽  
pp. 201-208 ◽  
Author(s):  
S. Sewak ◽  
S. Kosmider ◽  
V. Ganju ◽  
A. Woollett ◽  
E. G. Yeow ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Phase Ii ◽  
Metastatic Prostate Cancer ◽  
Phase Ii Study ◽  
Hormone Refractory

scholarly journals Phase II study of oxaliplatin versus oxaliplatin combined with infusional 5-fluorouracil in hormone refractory metastatic prostate cancer patients

2003 ◽  
Vol 14 (8) ◽  
pp. 1291-1298 ◽  
Author(s):  
J.P. Droz ◽  
X. Muracciole ◽  
N. Mottet ◽  
M. Ould Kaci ◽  
J.M. Vannetzel ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Phase Ii ◽  
Metastatic Prostate Cancer ◽  
Phase Ii Study ◽  
Hormone Refractory

Docetaxel, Vinorelbine, and Zoledronic Acid as First-Line Treatment in Patients with Hormone Refractory Prostate Cancer: A Phase II Study

2007 ◽  
Vol 52 (4) ◽  
pp. 1020-1027 ◽  
Author(s):  
Giuseppe Di Lorenzo ◽  
Riccardo Autorino ◽  
Sisto Perdonà ◽  
Michele De Laurentiis ◽  
Massimo D'Armiento ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Zoledronic Acid ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Hormone Refractory Prostate Cancer ◽  
Line Treatment ◽  
First Line ◽  
Hormone Refractory ◽  
First Line Treatment
Sign in / Sign up

Export Citation Format

Share Document